ITER Organization Chooses Bertin Technologies to Design a Density Interferometer Polarimeter
Bertin Technologies , a subsidiary of CNIM Group , has received a contract from ITER Organization for the preliminary design of the “Density Interferometer Polarimeter” (DIP), a complex optical diagnostic system that measures plasma density during nuclear fusion reactions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005118/en/
“Density Interferometer Polarimeter” (DIP) Copyright Bertin Technologies
This is a key component of the tokamak reactor’s future diagnostic instruments. The purpose of the DIP will be to help control plasma by measuring the density of the electrons in order to ensure its stability and obtain an optimal energy yield.
Optical instrumentation design and manufacturing, such as the DIP technology, are key areas of excellence at Bertin Technologies, the French leader of industrial innovation for this field. Collaborating with the ITER program since 2009, through contracts with the ITER Organization at Cadarache, Fusion For Energy in Barcelona and Princeton Physics Plasma Laboratory in the USA, Bertin Technologies has developed itself in instrumentation designed to analyze fusion plasma, contributing to the control and safety of experiments as well as acquiring parametric data that will be used by physicians. Building on its unique experience and expertise, Bertin’s objective for the coming years is to take charge of other aspects of complete diagnostics for ITER, from the design phase to the installation on site.
ABOUT BERTIN TECHNOLOGIES
BERTIN TECHNOLOGIES, subsidiary of CNIM Group, relies on its long history of innovation to develop, produce and market innovative systems and equipment worldwide. Among its 700 employees, there are 2/3 engineers and high-level managers. The company is active worldwide and its turnover amounts to nearly 100 million euros in 2017.
Based on his experience in the Megajoule Laser program, Bertin has positioned himself since 2009 on instrumentation intended to analyze the fusion plasma to contribute to the conduct and safety of ITER Organization's experiments, but also to acquire the parameters that will be operated by physicians. With the acquisition in 2017 of Winlight, a French company specializing in the design and manufacturing of components and systems for high performance optics, Bertin strengthens its presence in the field of Big Science (research reactors, synchrotrons, telescopes) and for major defense and space programs, with customers in Europe, the United States and Asia.
Tel : + 33 1 43 59 29 84
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation18.4.2019 10:00:00 CEST | Pressemelding
Phyton Biotech, a German/North American Plant Cell Fermentation (PCF®) technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, are pleased to announce today that they have received European approval from the EDQM (European Directorate of Quality Medicines) for AqVida’s paclitaxel injectable FDF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005161/en/ Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF® technology process. Under the strategic partnership with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida’s Taxol generic formulation, which is produced in AqVida’s new state-of-the-art injectable manufacturing facility located in Dassow, Germany. AqVida’s ultramodern robotic manufacturing line, designed for filling cytotoxic injectables, will be utilized to pro
Racketeering Lawsuit Filed by Boies Schiller Flexner LLP Alleges Czech Oligarch Defrauds US Hedge Fund and Former Partner Out of Over $1 Billion18.4.2019 07:41:00 CEST | Pressemelding
New York hedge fund, Kingstown Capital Management L.P, and other plaintiffs filed a lawsuit on 10 April 2019 in the Southern District of New York against Radovan Vitek, a Czech real estate mogul with business interests throughout Europe, whose fortune Forbes magazine estimates at $3.5 billion. Represented by litigation powerhouse Boies Schiller Flexner LLP, the hedge fund Kingstown Capital Management L.P and Czech investment firm Investhold Ltd allege that Vitek ran an elaborate criminal enterprise that defrauded the plaintiffs out of more than US $1 billion. According to the complaint, Berlin’s largest commercial real estate landlord, Vitek engaged in racketeering activity including wire fraud, mail fraud, money laundering, and other crimes and amassed his wealth at the expense of the plaintiffs, according to the complaint. His commercial interests span multiple jurisdictions including the Czech Republic, Switzerland, Luxembourg, Germany, Croatia and UK. The complaint alleges that Vit
MHI Thermal Systems Develops Demonstration Unit of the World’s First Small-Capacity Residential Air-Conditioner Adopting the Low-GWP R454C Refrigerant18.4.2019 07:21:00 CEST | Pressemelding
Premiering for the first time in the world, Mitsubishi Heavy Industries Thermal Systems, Ltd., a Group company of Mitsubishi Heavy Industries, Ltd. (MHI) (TOKYO: 7011), is adopting R454C, a refrigerant with an extremely low global warming potential (GWP), in a 1-horsepower (HP) class residential air-conditioner. The conventional shortcomings of the R454C,for example; inferior heat exchanger performance attributable to it being a mixed refrigerant have been overcome through the use of proprietary technology that optimize the heat exchanger’s flow volume and other measures. The company has already developed a demonstration unit of the residential air-conditioner featuring R454C and preparations are underway towards mass production with an eye on an initial launch into the European market, where environmental regulations are particularly stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005241/en/ Residential type
Hologic Receives European CE Mark for ThinPrep® Genesis Processor, an Automated Cytology Slide and Molecular Sample System18.4.2019 07:00:00 CEST | Pressemelding
Hologic, Inc. (Nasdaq: HOLX) announced today that the ThinPrep® Genesis processor for cytology slide and molecular test preparation has received a CE IVD mark in Europe. The system features increased automation capabilities, together with ergonomic and chain of custody benefits, compared to older instruments. Most importantly, the instrument will prepare slides for cytology as well as aliquot samples for molecular testing, reducing manual sample handling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005130/en/ ThinPrep Genesis processor (Photo: Business Wire) The Genesis processor is the latest extension of the ThinPrep portfolio, which revolutionized and increased the accuracy of cervical cancer screening with the first liquid-based Pap test in 1996. Hologic launched an updated ThinPrep® 2000 processor in 2017 and received FDA approval in 2018 for the ThinPrep® Integrated Imager, which guides cytotechnologists to ar
Ipsen Completes Acquisition of Clementia Pharmaceuticals18.4.2019 05:00:00 CEST | Pressemelding
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior Court. Pursuant to the arrangement, Clementia shareholders will receive US$25.00 per share in cash upfront and one contingent value right (CVR) per share entitling them to receive US$6.00 per CVR upon the U.S. Food and Drug Administration's (FDA) acceptance of the regulatory filing for palovarotene for the treatment of multiple osteochondromas (MO). Clementia’s key late-stage clinical asset palovarotene is an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of two rare bone disorders, fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), and other diseases. The palovarotene regulatory submission for the prevention of heterotopic ossification (HO) in patients with FOP in the U.S.
Sartorius Starts off Fiscal 2019 with a Strong First Quarter18.4.2019 05:00:00 CEST | Pressemelding
Sartorius, a leading international partner of biopharmaceutical research and the industry, started off fiscal 2019 with substantial double-digit growth in order intake, sales revenue and earnings. Consolidated first-quarter sales revenue rose in constant currencies by 16.8% to 435.7 million (reported: +19.4%); order intake increased 16.6% to 482.8 million euros (reported: +19.3%). Sartorius’ underlying EBITDA1) surged 28.7% to 114.0 million euros. Its respective underlying EBITDA margin for the first three months of 2019 was 26.2% (Q1 2018: 24.3%), with a good half a percentage point of this increase resulting from the change in accounting rules2), as expected. Relevant net profit3) for the Group climbed 30.8% to 48.6 million euros. Earnings per ordinary share were 0.71 euros (Q1 2018: 0.54 euros); earnings per preference share, 0.72 euros (Q1 2018: 0.55 euros). “We are very pleased with our first-quarter results,” said Dr. Joachim Kreuzburg, CEO and Executive Board Chairman. “In Biopr